This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Arteriovenous Malformation of Cerebral Vessels뇌의 동정맥기형 (뇌동정맥기형)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q28.2 (arteriovenous malformation of cerebral vessels) | Special Copayment Reduction: V191 (special copayment reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsCerebral arteriovenous malformation, intracranial arteriovenous malformation, cerebral AVM, intracranial AVM, brain AVM, congenital cerebrovascular arteriovenous malformation
C. Adult onsetCongenital, but symptom onset is concentrated mainly in the 20s–40s; often first discovered through intracranial hemorrhage, epileptic seizures or headache.
1. HistoryA summary of the key milestones in brain AVM research, from Virchow's pathological descriptions to the Spetzler-Martin grade.
2. CausesAbnormal embryonic vasculogenesis; disruption of the VEGF, Notch and TGF-β pathways leads to direct arteriovenous connections without capillary development.
3. GeneticsMostly sporadic; related genetic mechanisms include HHT (ENG, ACVRL1), RASA1 and KRAS somatic mutations.
4. General epidemiologyPrevalence about 10–18 per 100,000; annual diagnosis rate about 1–1.5 per 100,000; slightly more common in men.
5. PathophysiologyWith no capillaries in the nidus, arterial high pressure is transmitted directly to the venous system, creating a triple risk of hemorrhage, ischemia and venous hypertension.
6. SymptomsShows varied presentations, including intracranial hemorrhage (50%), epilepsy (25–30%), headache, focal neurological deficits and cognitive impairment.
7. SignsSigns of meningeal irritation, focal neurological deficits and raised intracranial pressure; unruptured AVMs may show no abnormalities on physical examination.
8. ScreeningBrain MRI is the most effective screening test; non-contrast CT comes first for acute headache or neurological abnormalities.
9. DiagnosisDSA is the diagnostic standard; CTA and MRA define the 3D anatomy; risk is classified by the Spetzler-Martin grade.
10. TreatmentOptions are surgical resection (Spetzler-Martin I–III), radiosurgery (small and deep lesions), embolization (alone or adjunctive) and combined treatment.
11. PrognosisOnce complete obliteration is achieved, the risk of hemorrhage is nearly 0; without treatment, an annual hemorrhage risk of 2–4% persists.
12. PreventionPrimary prevention is not possible because it is congenital; blood pressure control, family screening for HHT and management of hemorrhage risk factors are the core of secondary prevention.
13. ReferencesMohr JP et al. Medical management with or without interventional therapy for unruptured brain AVMs (ARUBA) … and 9 other papers

1. History

Medical recognition of cerebral arteriovenous malformation (AVM) begins in the mid-19th century, when the German pathologist Rudolf Virchow observed and described cerebral vascular malformation tissue under the microscope. In 1863 Virchow classified vascular malformation tissue under the term angioma racemosum, and Steinheil (1895) later reported the first clinical case of cerebral arteriovenous malformation in detail.

In the early 20th century, the Swiss neuropathologists Cushing and Bailey systematically classified cerebral vascular malformations, laying the foundation for research on vascular malformations. Egas Moniz's development of cerebral angiography in 1927 made antemortem diagnosis possible, and in the 1940s–1950s pioneering neurosurgeons such as Walter Dandy and Norman Dott began to succeed in surgical resection of brain AVMs. Dandy first reported successful surgical resection of a brain AVM in 1928.

In the 1960s–1970s, the introduction of the operating microscope advanced microneurosurgery and greatly improved the precision and safety of brain AVM surgery. The introduction of CT in the 1970s and MRI in the 1980s made noninvasive diagnosis possible, and long-term follow-up studies on the natural history of vascular malformations began to accumulate.

In 1986 Robert Spetzler and Neil Martin published the Spetzler-Martin grading system to predict the surgical risk of AVMs. This system classifies surgical risk into grades I–V by summing lesion size (small 1 point, medium 2 points, large 3 points), proximity to eloquent brain (non-eloquent 0 points, eloquent 1 point) and deep venous drainage (superficial 0 points, deep 1 point), and it is still used as the clinical standard today.

With the development of the Gamma Knife by Lars Leksell of Sweden in 1987, radiosurgery emerged as a major option for AVM treatment. Since the 1990s, advances in endovascular embolization materials and techniques (Onyx liquid embolic agent, introduced in 2005), elucidation of AVM pathogenesis through genomic research in the 2010s, and discussion of treatment strategies for unruptured AVMs through the ARUBA study (2014, Lancet) have shaped the main currents of current brain AVM research.


2. Causes

Cerebral arteriovenous malformation is a congenital vascular anomaly in which abnormalities in the vasculogenesis and vascular remodeling stages of embryonic development result in a direct connection (nidus) between arteries and veins, without formation of a capillary network.

In normal embryonic vascular development, various signaling molecules—vascular endothelial growth factor (VEGF), Notch signaling, the Ephrin-B2/EphB4 axis, the TGF-β/BMP pathway and the Angiopoietin-Tie2 axis—coordinate the determination of arterial and venous identity, capillary proliferation and pruning. An abnormality in any of these pathways can lead to formation of a direct arteriovenous connection.

Abnormalities of the Notch signaling pathway in particular are drawing attention. Overactivation of Notch1 and Notch4 has been experimentally shown to induce AVM-like vascular abnormalities in animal models. VEGF overexpression is also known to contribute to abnormal vascular proliferation and the formation of arteriovenous connections. HHT-related genes (ENG, ACVRL1) are components of the TGF-β receptor complex that regulate the survival, proliferation and migration of vascular endothelial cells, and defects in these genes are a direct cause of AVM formation.

Somatic mutations are also recognized as an important cause of sporadic AVMs. Recent studies have reported that gain-of-function somatic mutations in RAS-MAPK pathway genes such as KRAS, MAP2K1 and BRAF are found at high frequency in AVM tissue. These mutations promote abnormal activation, proliferation and migration of vascular endothelial cells, contributing to AVM formation.


3. Genetics

About 95% of cerebral arteriovenous malformations occur sporadically and show no clear familial inheritance pattern. The remaining approximately 5% are associated with genetic syndromes.

Hereditary hemorrhagic telangiectasia (HHT) is the genetic disease most closely associated with brain AVM; HHT type 1 (ENG gene, 9q34) and HHT type 2 (ACVRL1 gene, 12q13) are inherited in an autosomal dominant manner. Brain AVMs are found in about 5–20% of HHT patients, and many of these are characteristically multiple. HHT type 3 is associated with SMAD4 gene mutations and carries a high risk of multiple brain AVMs at a young age.

RASA1 gene (12q21) mutations are associated with capillary malformation–arteriovenous fistula–Parkes Weber syndrome (CM-AVM), and an association with brain AVM has also been reported. RASA1 encodes a RAS-GTPase–activating protein, and loss of function of this gene overactivates the RAS-MAPK pathway, leading to vascular malformations.

In sporadic brain AVMs, a study reported that KRAS G12V/G12D mutations are found at a high frequency of about 40–50% in endothelial cells of AVM tissue (Nikolaev et al., Science, 2018). This suggests that AVMs have the character of a "vascular neoplasm" driven by somatic mutation, and points to the possibility of therapies targeting the RAS-MAPK pathway, such as MEK inhibitors (binimetinib, etc.). In clinical practice, genetic testing is performed selectively in patients suspected of having HHT.


4. General epidemiology

The prevalence of brain AVM is estimated in various studies at about 10–18 per 100,000 population. The annual frequency of new diagnoses (incidence) is about 1–1.5 per 100,000 population. Worldwide, about 300,000 to 1,000,000 people are estimated to have a brain AVM.

The sex distribution is reported to be slightly male-predominant, with a male-to-female ratio of about 1.1–1.2:1, but the difference is small. The median age at first diagnosis of symptomatic presentation is about the 30s–40s, and a considerable proportion present in their teens and 20s. Presentation with intracranial hemorrhage accounts for about 50%, with epileptic seizures about 25–30%, and with headache or neurological deficits the remainder.

Data on racial and ethnic differences are limited, but some studies report a higher rate of hemorrhagic presentation in patients of Asian descent. Epidemiological data from East Asian countries, including Korea, are gradually accumulating through national stroke registries. With increasing use of MRI, incidental detection of asymptomatic AVMs is becoming more frequent, increasing the importance of natural history data in treatment decisions.


5. Pathophysiology

The pathophysiology of brain AVM can be understood in three aspects: hemodynamic abnormalities centered on the nidus, effects on surrounding brain tissue and vessel wall abnormalities.

Hemodynamic abnormalities: Because the nidus has no capillaries, high-pressure arterial flow (mean arterial pressure 80–100 mmHg) is transmitted directly to the venous system (mean venous pressure 10–15 mmHg). As a result, feeding arteries gradually dilate from increased flow, and draining veins are exposed to arterial pressure, leading to venous arterialization and venous hypertension. Venous hypertension causes impaired venous drainage, venous thrombosis and venous rupture.

Steal ischemia (cerebral steal): AVM vessels have impaired autoregulation, and because blood flow is preferentially supplied to the AVM as a high-flow channel, a steal phenomenon occurs in which blood flow to surrounding normal brain tissue decreases. This causes focal neurological symptoms and epilepsy.

Mechanisms of hemorrhage risk: The vessel walls in the nidus lack an elastic layer and smooth muscle and are much more fragile than normal vessels. Focal high-pressure zones within the nidus, microaneurysms of feeding arteries or within the nidus (intranidal aneurysm), and increased intranidal pressure from venous outflow stenosis are direct causes of hemorrhage. At the molecular level, oxidative stress, vascular endothelial growth factor (VEGF) overexpression and vessel wall degradation from MMP overactivity raise the risk of hemorrhage.


6. Symptoms

The clinical symptoms of brain AVM are broadly divided by presentation into hemorrhagic, epileptic, headache and neurological deficit types.

Intracranial hemorrhage is the most serious and common initial presentation, accounting for about 50% of all presentations. It is accompanied by sudden severe headache, nausea and vomiting, decreased consciousness and focal neurological deficits, and may appear as intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH) or subarachnoid hemorrhage (SAH). The mortality of the first hemorrhage is about 10–15%, and the rate of neurological disability is about 30–50%.

Epileptic seizures are the initial presenting symptom in about 25–30% of all cases. Seizures are more frequent when the AVM is located in the cerebral cortex, especially in the temporal and parietal lobes. Seizures can take various forms, such as focal seizures and secondarily generalized tonic-clonic seizures, and some progress to intractable epilepsy.

Headache is the initial symptom in about 15–20% and may appear in a migraine-like form or as a nonspecific headache. A causal relationship with the AVM is difficult to establish from headache alone, and the diagnosis is often linked to the headache after the AVM is found incidentally on imaging. Focal neurological deficits arise from steal ischemia or venous hypertension and appear as various symptoms depending on the AVM's location, such as unilateral weakness, sensory disturbance, visual field defects and aphasia.


7. Signs

Physical examination findings in brain AVM vary with the presence of hemorrhage and the size and location of the lesion.

When hemorrhage occurs, signs of meningeal irritation (neck stiffness, Kernig sign, Brudzinski sign), decreased level of consciousness (falling Glasgow Coma Scale), pupillary abnormalities (pupil dilation, loss of the light reflex, abducens palsy) and Cushing's triad of hypertension, bradycardia and irregular respiration (with extreme elevation of intracranial pressure) are observed. Focal neurological deficits—hemiplegia, aphasia, hemianopia, eye movement disorders—vary with the site of hemorrhage.

In unruptured AVMs, there are often no abnormalities at all on physical examination. A bruit may be heard on auscultation over the scalp or skull, and especially with large AVMs a bruit may also be detected on auscultation over the eyelids or orbit. Todd paralysis (transient unilateral paralysis after a seizure) may be found after an epileptic seizure.

Neurological examination systematically evaluates dysfunction according to the AVM's location—motor function, language, visual fields, cerebellar function and cranial nerve function. As a sign of raised intracranial pressure, papilledema may be seen on funduscopic examination, and when hydrocephalus accompanies a progressive brain AVM, the triad of gait disturbance, cognitive decline and urinary incontinence due to ventricular enlargement may appear.


8. Screening

Screening for brain AVM depends on the clinical situation.

Brain MRI is the screening test that best visualizes brain AVMs noninvasively and without radiation exposure. On T2-weighted images, signal voids (loss of signal due to blood flow), clusters of vessels and hemosiderin deposits suggesting prior hemorrhage (dark areas on T2* or SWI) strongly suggest an AVM. Performing MR angiography (MRA) at the same time allows noninvasive assessment of vascular structure.

With acute neurological abnormalities or sudden severe headache, non-contrast brain CT is performed first to check for acute intracranial hemorrhage. If hemorrhage is confirmed on CT, CTA or DSA is immediately added to evaluate vascular malformations such as AVMs and aneurysms.

Brain MRI screening is recommended for patients diagnosed with HHT and their first-degree relatives. In patients with epilepsy that responds inadequately to antiseizure drugs, or when atypical headache persists, evaluation for a structural cause with brain MRI is also needed. If screening is positive, DSA or CTA/MRA is performed for confirmation.


9. Diagnosis

Digital subtraction angiography (DSA) is the standard for diagnosing brain AVM. It most accurately evaluates the feeding arteries, the structure and size of the nidus, the route and morphology of the draining veins, the transit time of blood flow and the presence of associated aneurysms. Whole-brain angiography including both internal carotid arteries and the vertebral arteries is performed, taking care not to miss associated aneurysms or venous abnormalities.

CTA is useful for rapidly defining the anatomy of the AVM and its relationship to adjacent brain structures through 3D reconstruction and is suitable for rapid evaluation in emergencies. MRI and MRA offer excellent soft tissue resolution and are used to evaluate the relationship of the nidus to eloquent cortex and traces of prior hemorrhage. Functional MRI (fMRI) and diffusion tensor imaging (DTI) are used for preoperative evaluation of the anatomical relationship between the lesion and functional cortex and white matter.

The Spetzler-Martin grading system is the standard for lesion classification. Size (< 3 cm: 1 point, 3–6 cm: 2 points, > 6 cm: 3 points), proximity to eloquent brain areas (non-eloquent: 0 points, eloquent: 1 point) and venous drainage pattern (superficial: 0 points, deep: 1 point) are summed to classify lesions into grades I–V. The higher the grade, the greater the surgical risk. The Lawton-Young supplementary grading system is sometimes used as an adjunct.


10. Treatment

Treatment of brain AVM is decided jointly by a multidisciplinary team (neurosurgery, interventional neuroradiology, radiation oncology) according to lesion characteristics, patient age and clinical condition, and Spetzler-Martin grade.

Microsurgical resection is the first-line treatment offering the prospect of cure in Spetzler-Martin grade I–III AVMs. Under the operating microscope, the feeding arteries are occluded and the nidus is dissected free from the surrounding brain tissue and resected. Complete obliteration is confirmed by DSA immediately after surgery. In experienced surgical teams, the surgical cure rate for Spetzler-Martin grade I–II AVMs exceeds 95%.

Stereotactic radiosurgery (SRS) delivers focused high-dose radiation to the nidus using the Gamma Knife, LINAC or CyberKnife. Radiation stimulates the endothelial cells of the vessel wall, leading to gradual vascular occlusion; complete obliteration takes 2–4 years. It is particularly preferred for AVMs less than 3 cm in diameter, in deep locations (basal ganglia, thalamus, brainstem) and of high grade. The risk of hemorrhage persists during the period before obliteration (latency period).

Endovascular embolization often cannot achieve complete obliteration on its own, so it is used to reduce lesion size before surgical resection or radiosurgery. Liquid embolic agents such as Onyx and NBCA (n-butyl cyanoacrylate) are injected into the nidus via the feeding arteries. Rarely, complete obliteration can be achieved with embolization alone in AVMs with small, simple feeding arteries. Combined treatment (embolization + surgical resection, or embolization + SRS) is used to improve treatment efficacy in large, high-grade AVMs.


11. Prognosis

The prognosis of brain AVM varies greatly depending on whether and how it is treated. In the natural history of untreated AVM, the annual risk of hemorrhage is about 2–4%, and after a hemorrhage the risk of rebleeding rises to about 6–18% within the first year. Hemorrhage leads to serious outcomes, with a mortality rate of 10–15% and a rate of permanent neurological disability of 20–50%.

When complete obliteration is achieved, the subsequent risk of hemorrhage falls to a level similar to that of the general population, and the prognosis depends mainly on the preoperative neurological status and the presence of surgical complications. After surgical resection of Spetzler-Martin grade I–II AVMs, a good neurological outcome (mRS 0–2) is achieved in more than 90%. The 3-year obliteration rate after radiosurgery is about 60–80% (for small, low-grade AVMs), and retreatment is needed if obliteration fails or the lesion recurs.

Regarding treatment of unruptured AVMs, the ARUBA study (2014) suggested that observation is superior, but controversy continues owing to limitations in the study methodology. The current standard is an individualized multidisciplinary decision that considers patient age, lesion characteristics and institutional expertise. Long-term follow-up studies have reported hemorrhage or death within 10 years in about one-third of untreated patients, underscoring the importance of the treatment decision.


12. Prevention

Because brain AVM is a congenital vascular malformation, primary prevention is currently not possible. Prevention strategies focus on secondary prevention.

Management of hemorrhage risk factors is most important. Hypertension is an independent risk factor for AVM hemorrhage, and aggressive blood pressure control (target < 130/80 mmHg) is recommended. Anticoagulants (warfarin, NOACs) should be avoided in AVM patients where possible, or used cautiously only when absolutely necessary. Because pregnancy increases the hemodynamic load and raises the risk of rupture, it is advisable for AVM patients planning a pregnancy to make a treatment decision beforehand.

As secondary prevention related to genetic syndromes, brain MRI screening and regular follow-up are recommended for patients with HHT and their families. When an AVM is found in an HHT patient, the decision on treatment is made after evaluation by a multidisciplinary specialist team. As a future direction for drug therapy, KRAS/MEK pathway inhibitors are being explored for their potential to shrink AVM lesions, and some small studies have reported encouraging results, but they are not currently a clinical standard. Regular follow-up after diagnosis (brain MRI, neurology outpatient visits) to detect lesion changes, signs of hemorrhage and neurological abnormalities early is key to preventing complications.


13. References

  1. Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383(9917):614-621. DOI: 10.1016/S0140-6736(13)62302-8. PMID: 24461883.

  2. Nikolaev SI, Vetiska S, Bonilla X, et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med. 2018;378(3):250-261. DOI: 10.1056/NEJMoa1709449. PMID: 29342388.

  3. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65(4):476-483. DOI: 10.3171/jns.1986.65.4.0476. PMID: 3760956.

  4. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg. 2013;118(2):437-443. DOI: 10.3171/2012.10.JNS121280. PMID: 23140129.

  5. van Beijnum J, van der Worp HB, Buis DR, et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011;306(18):2011-2019. DOI: 10.1001/jama.2011.1632. PMID: 22068990.

  6. Starke RM, Yen CP, Ding D, Sheehan JP. A practical grading scale for predicting outcome after radiosurgery for arteriovenous malformations. J Neurosurg. 2013;119(4):981-987. DOI: 10.3171/2013.5.JNS122296. PMID: 23829840.

  7. Kim H, Su H, Weinsheimer S, et al. Brain arteriovenous malformation pathogenesis: a response-to-injury paradigm. Acta Neurochir Suppl. 2011;111:83-92. DOI: 10.1007/978-3-7091-0693-8_14. PMID: 21725740.

  8. Willemse RB, Mager JJ, Westermann CJ, et al. Bleeding risk of cerebrovascular malformations in hereditary hemorrhagic telangiectasia. J Neurosurg. 2000;92(5):779-784. DOI: 10.3171/jns.2000.92.5.0779. PMID: 10794290.

  9. Stapf C, Mast H, Sciacca RR, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology. 2006;66(9):1350-1355. DOI: 10.1212/01.wnl.0000210524.68507.87. PMID: 16682666.

  10. Berman MF, Sciacca RR, Pile-Spellman J, et al. The epidemiology of brain arteriovenous malformations. Neurosurgery. 2000;47(2):389-396. DOI: 10.1097/00006123-200008000-00023. PMID: 10942013.